Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension

• Status: Completed
• Trial end date: 2004-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effects of two different antihypertensive medications in the drug class of beta-blockers on control of glucose in Type II diabetic patients with high blood pressure.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Carvedilol; Metoprolol

Criteria

Inclusion criteria:

• Patients at screening must be insulin producing Type II diabetics (C peptide positive).

• Must have a history of mild to moderate hypertension (140-179 systolic; 90-1-9 diastolic).

• Must be on stable regimen of ACE (angiotensin converting enzyme) / ARB (angiotensin receptor blocker) treatment alone or in combination with other treatments.

• Patient''s laboratory result for HbA1c must be 6.5 - 8.5 (drug treated) or 6.5 - 7.5 (diet alone).

• Must be on a stable antidiabetic regimen (drug treated or diet alone).

Exclusion criteria:

• Patients using beta-blocker therapy.